Cytomedix names new vice president of business development

As vice president of business development, Dr Clausen, who has been a consultant to Cytomedix since May 2008, will be responsible for the coordination of the investigational new drug submission and Phase I study of its CT-112 peptide, an anti-inflammatory peptide that has shown favorable pre-clinical activity.

Dr Clausen will also spearhead the cultivation of collaborative agreements and research grants, including licensing opportunities, surrounding the company’s proprietary AutoloGel system, as well as providing scientific support for the sales, marketing, and reimbursement efforts.

Dr Clausen joins Cytomedix after nearly seven years as a founding member and vice president of research and development at Marligen Bioscience, an Ijamsville, Maryland-based company that develops, manufactures and markets innovative products for the life sciences market. Dr Clausen holds a bachelor of science degree in biochemistry from Beloit College and a PhD in biochemistry from Rush University.

Martin Rosendale, CEO of Cytomedix, said: “We are delighted to have a scientist of Dr Clausen’s caliber join our management team. Pete’s experience in the biotechnology sector, primarily in the research and development of new products, will further our efforts in the development of our CT-112 peptide, as well as help facilitate collaborative agreements regarding our AutoloGel system and other technologies.”